Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.
Executive Summary
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.
You may also be interested in...
Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps
Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.
Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps
Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.
Eisai/Janssen Aciphex Sales Closing In On $250 Mil. 13 Months After Launch
Janssen/Eisai's proton pump inhibitor Aciphex (rabeprazole) is closing in on $250 mil. in sales after 13 months on the market, Eisai U.S. Chairman Soichi Matsuno indicated Oct. 3 at a UBS Warburg Global Life Sciences Conference in New York City.